450 related articles for article (PubMed ID: 17523848)
21. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator.
Ahn GO; Botting KJ; Patterson AV; Ware DC; Tercel M; Wilson WR
Biochem Pharmacol; 2006 Jun; 71(12):1683-94. PubMed ID: 16620789
[TBL] [Abstract][Full Text] [Related]
22. Chemical radiosensitizers for use in radiotherapy.
Wardman P
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
[TBL] [Abstract][Full Text] [Related]
23. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
Wilson WR; Stribbling SM; Pruijn FB; Syddall SP; Patterson AV; Liyanage HD; Smith E; Botting KJ; Tercel M
Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
Palmer BD; Wilson WR; Anderson RF; Boyd M; Denny WA
J Med Chem; 1996 Jun; 39(13):2518-28. PubMed ID: 8691449
[TBL] [Abstract][Full Text] [Related]
25. A redox-silent analogue of tocotrienol inhibits hypoxic adaptation of lung cancer cells.
Kashiwagi K; Harada K; Yano Y; Kumadaki I; Hagiwara K; Takebayashi J; Kido W; Virgona N; Yano T
Biochem Biophys Res Commun; 2008 Jan; 365(4):875-81. PubMed ID: 18042466
[TBL] [Abstract][Full Text] [Related]
26. Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.
Hong CR; Mehta SY; Liyanage HDS; McManaway SP; Lee HH; Jaiswal JK; Bogle G; Tercel M; Pruijn FB; Wilson WR; Hicks KO
Cancer Chemother Pharmacol; 2021 Oct; 88(4):673-687. PubMed ID: 34245333
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
28. 1,2-benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation.
Jain M; Kwon CH
J Med Chem; 2003 Dec; 46(25):5428-36. PubMed ID: 14640551
[TBL] [Abstract][Full Text] [Related]
29. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
[TBL] [Abstract][Full Text] [Related]
30. Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.
Hong CR; Bogle G; Wang J; Patel K; Pruijn FB; Wilson WR; Hicks KO
Front Pharmacol; 2018; 9():1013. PubMed ID: 30279659
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: radiolytic reduction and cytotoxicity characteristics.
Tanabe K; Makimura Y; Tachi Y; Imagawa-Sato A; Nishimoto S
Bioorg Med Chem Lett; 2005 May; 15(9):2321-4. PubMed ID: 15837317
[TBL] [Abstract][Full Text] [Related]
32. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
33. Tumor hypoxia in cancer therapy.
Brown JM
Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
[TBL] [Abstract][Full Text] [Related]
34. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.
Hay MP; Denny WA; Wilson WR
Anticancer Drug Des; 1996 Jul; 11(5):383-402. PubMed ID: 8765531
[TBL] [Abstract][Full Text] [Related]
35. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
Gu Y; Guise CP; Patel K; Abbattista MR; Li J; Sun X; Atwell GJ; Boyd M; Patterson AV; Wilson WR
Cancer Chemother Pharmacol; 2011 Mar; 67(3):543-55. PubMed ID: 20473609
[TBL] [Abstract][Full Text] [Related]
36. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.
Duan JX; Jiao H; Kaizerman J; Stanton T; Evans JW; Lan L; Lorente G; Banica M; Jung D; Wang J; Ma H; Li X; Yang Z; Hoffman RM; Ammons WS; Hart CP; Matteucci M
J Med Chem; 2008 Apr; 51(8):2412-20. PubMed ID: 18257544
[TBL] [Abstract][Full Text] [Related]
37. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
[TBL] [Abstract][Full Text] [Related]
38. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.
Henderson ND; Plumb JA; Robins DJ; Workman P
Anticancer Drug Des; 1996 Sep; 11(6):421-38. PubMed ID: 8836108
[TBL] [Abstract][Full Text] [Related]
40. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm.
Wei MX; Tamiya T; Rhee RJ; Breakefield XO; Chiocca EA
Clin Cancer Res; 1995 Oct; 1(10):1171-7. PubMed ID: 9815909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
